# Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

> **NCT03996408** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Advanced Cholangiocarcinoma

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** TQB2450

## Key facts

- **NCT ID:** NCT03996408
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-24
- **Primary completion:** 2020-12-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03996408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03996408, "Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03996408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*